{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:13:31Z","timestamp":1793722411867,"version":"4.6.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"am","delay-in-days":297,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","award":["1069"],"award-info":[{"award-number":["1069"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.intimp.2024.112538","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T21:35:48Z","timestamp":1719351348000},"page":"112538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["PLGA nanoparticle-delivered Leishmania antigen and TLR agonists as a therapeutic vaccine against cutaneous leishmaniasis in BALB\/c mice"],"prefix":"10.1016","volume":"138","author":[{"given":"Asal","family":"Katebi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Riazi-rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyhaneh","family":"Varshochian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5052-2523","authenticated-orcid":false,"given":"Soheila","family":"Ajdary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.112538_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111671","article-title":"Host immune response against leishmaniasis and parasite persistence strategies: A review and assessment of recent research","volume":"139","author":"Elmahallawy","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.intimp.2024.112538_b0010","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3390\/microorganisms8081201","article-title":"Leishmania Immunity: Advancing Immunotherapy and Vaccine Development","volume":"8","author":"Ikeogu","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.intimp.2024.112538_b0015","doi-asserted-by":"crossref","unstructured":"A.C. Costa-da-Silva D. de O. Nascimento, J.R.M. Ferreira, K. Guimar\u00e3es-Pinto, L. Freire-de-Lima, A. Morrot, D. Decote-Ricardo, A.A. Filardy, C.G. Freire-de-Lima, Immune Responses in Leishmaniasis: An Overview Tropical Medicine and Infectious Disease 7 2022 54 10.3390\/tropicalmed7040054.","DOI":"10.3390\/tropicalmed7040054"},{"key":"10.1016\/j.intimp.2024.112538_b0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/14760584.2018.1459191","article-title":"Vaccine candidates against leishmania under current research","volume":"17","author":"Iborra","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.intimp.2024.112538_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1096458","article-title":"Immunotherapy and immunochemotherapy in combating visceral leishmaniasis","volume":"10","author":"Yadagiri","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2024.112538_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2021.105021","article-title":"Potential of TLR agonist as an adjuvant in Leishmania vaccine against visceral leishmaniasis in BALB\/c mice","volume":"158","author":"Goyal","year":"2021","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.intimp.2024.112538_b0035","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.4049\/jimmunol.1000238","article-title":"Applying TLR Synergy in immunotherapy: implications in cutaneous leishmaniasis","volume":"185","author":"Raman","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.112538_b0040","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1128\/IAI.01388-10","article-title":"Toll-Like Receptors Participate in Macrophage Activation and Intracellular Control of Leishmania (Viannia) panamensis","volume":"79","author":"Gallego","year":"2011","journal-title":"Infect. Immun."},{"key":"10.1016\/j.intimp.2024.112538_b0045","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1016\/j.vaccine.2009.09.066","article-title":"Optimized subunit vaccine protects against experimental leishmaniasis","volume":"27","author":"Bertholet","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2024.112538_b0050","volume":"X 4","author":"Nascimento","year":"2020","journal-title":"Allopurinol Therapy Provides Long Term Clinical Improvement, but Additional Immunotherapy Is Required for Sustained Parasite Clearance"},{"key":"10.1016\/j.intimp.2024.112538_b0055","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1016\/j.vaccine.2010.08.092","article-title":"A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis","volume":"28","author":"Llanos-Cuentas","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2024.112538_b0060","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.exppara.2014.08.016","article-title":"Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis","volume":"146","author":"Eskandari","year":"2014","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.intimp.2024.112538_b0065","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.femsim.2004.05.008","article-title":"Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection","volume":"42","author":"Tewary","year":"2004","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"10.1016\/j.intimp.2024.112538_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120597","article-title":"Polymeric nanoparticle vaccines to combat emerging and pandemic threats","volume":"268","author":"Wibowo","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.intimp.2024.112538_b0075","series-title":"Nanoparticles for Rational Vaccine Design","first-page":"29","article-title":"Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles","author":"Grego","year":"2021"},{"key":"10.1016\/j.intimp.2024.112538_b0080","doi-asserted-by":"crossref","unstructured":"S. Ayari-Riabi N. Ben khalaf, B. Bouhaouala-Zahar, B. Verrier, T. Trimaille, Z. Benlasfar, M. Chenik, M. Elayeb, Polylactide Nanoparticles as a Biodegradable Vaccine Adjuvant: A Study on Safety, Protective Immunity and Efficacy against Human Leishmaniasis Caused by Leishmania Major Molecules 27 2022 8677 10.3390\/molecules27248677.","DOI":"10.3390\/molecules27248677"},{"key":"10.1016\/j.intimp.2024.112538_b0085","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.2147\/IJN.S141069","article-title":"Vaccination with poly(D, L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNF\u03b1-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis","volume":"12","author":"Margaroni","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.intimp.2024.112538_b0090","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1080\/21645515.2015.1117714","article-title":"PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity","volume":"12","author":"Silva","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.intimp.2024.112538_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111276","article-title":"Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates Leishmania major-infected-macrophages activation","volume":"137","author":"Katebi","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2024.112538_b0100","doi-asserted-by":"crossref","unstructured":"P. Kropf, I. M\u00fcller, K. Brunson, R. Etges, 4.2 The Leishmaniasis Model, in: S.H. Kaufmann, D. Kabelitz (Eds.), Methods in Microbiology, Academic Press, 1998: pp. 419\u2013458. Doi: 10.1016\/S0580-9517(08)70688-3.","DOI":"10.1016\/S0580-9517(08)70688-3"},{"key":"10.1016\/j.intimp.2024.112538_b0105","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nri.2016.72","article-title":"Cutaneous leishmaniasis: immune responses in protection and pathogenesis","volume":"16","author":"Scott","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.intimp.2024.112538_b0110","doi-asserted-by":"crossref","unstructured":"B.M. Roatt R.D. de O. Aguiar-Soares, L.E.S. Reis, J.M. de O. Cardoso, F.A.S. Mathias, R.C.F. de Brito, S.M. da Silva, N.D.F. Gontijo, S. de A. Ferreira, J.G. Valenzuela, R. Corr\u00eaa-Oliveira, R.C. Giunchetti, A.B. Reis, A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden Front. Immunol. 8 2017 accessed May 27, 2024 https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2017.00217.","DOI":"10.3389\/fimmu.2017.00217"},{"key":"10.1016\/j.intimp.2024.112538_b0115","doi-asserted-by":"crossref","first-page":"6433","DOI":"10.1016\/j.vaccine.2018.08.087","article-title":"Randomized, controlled, double-blinded field trial to assess Leishmania vaccine effectiveness as immunotherapy for canine leishmaniosis","volume":"36","author":"Toepp","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2024.112538_b0120","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1016\/j.vaccine.2016.09.016","article-title":"Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant","volume":"34","author":"Schaut","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2024.112538_b0125","doi-asserted-by":"crossref","unstructured":"Q. Zhu, C. Egelston, A. Vivekanandhan, S. Uematsu, S. Akira, D.M. Klinman, I.M. Belyakov, J.A. Berzofsky, Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: Implications for vaccines, Proceedings of the National Academy of Sciences 105 (2008) 16260\u201316265. Doi: 10.1073\/pnas.0805325105.","DOI":"10.1073\/pnas.0805325105"},{"key":"10.1016\/j.intimp.2024.112538_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2022.100122","article-title":"The critical role of Toll-like receptor-mediated signaling in cancer immunotherapy","volume":"14","author":"Chen","year":"2022","journal-title":"Medicine in Drug Discovery"},{"key":"10.1016\/j.intimp.2024.112538_b0135","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1348-0421.2007.tb03984.x","article-title":"Exposure to Leishmania major Modulates the Proportion of CD4T Cells without Affecting Cellular Immune Responses","volume":"51","author":"Alimohammadian","year":"2007","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.intimp.2024.112538_b0140","doi-asserted-by":"crossref","unstructured":"A. j, b. k, T helper (h)1\/Th2 and Leishmania: paradox rather than paradigm Immunol. Lett. 99 2005 10.1016\/j.imlet.2005.01.009.","DOI":"10.1016\/j.imlet.2005.01.009"},{"key":"10.1016\/j.intimp.2024.112538_b0145","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1002\/1521-4141(2002010)32:10<2923::AID-IMMU2923>3.0.CO;2-E","article-title":"An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection","volume":"32","author":"Alexander","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2024.112538_b0150","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/203818","article-title":"Reactive oxygen species and nitric oxide in cutaneous leishmaniasis","volume":"2012","author":"Horta","year":"2012","journal-title":"J Parasitol Res"},{"key":"10.1016\/j.intimp.2024.112538_b0155","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13071-017-2062-3","article-title":"The inflammatory cytokine effect of Pam3CSK4 TLR2 agonist alone or in combination with Leishmania infantum antigen on ex-vivo whole blood from sick and resistant dogs","volume":"10","author":"Mart\u00ednez-Orellana","year":"2017","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.intimp.2024.112538_b0160","first-page":"168","article-title":"TLR ligand suppression or enhancement of Treg cells?","volume":"27","author":"Conroy","year":"2008","journal-title":"A Double-Edged Sword in Immunity to Tumours, Oncogene"},{"key":"10.1016\/j.intimp.2024.112538_b0165","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1016\/j.molimm.2008.02.010","article-title":"Selective synergy in anti-inflammatory cytokine production upon cooperated signaling via TLR4 and TLR2 in murine conventional dendritic cells","volume":"45","author":"Hirata","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.intimp.2024.112538_b0170","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s11095-006-9208-x","article-title":"Encapsulation of nucleic acids and opportunities for cancer treatment","volume":"24","author":"Brannon-Peppas","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.intimp.2024.112538_b0175","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejpb.2016.05.018","article-title":"PLGA nanoparticles modified with a TNF\u03b1 mimicking peptide, soluble Leishmania antigens and MPLA induce T cell priming in vitro via dendritic cell functional differentiation","volume":"105","author":"Margaroni","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.intimp.2024.112538_b0180","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nri2097","article-title":"T H 1 cells control themselves by producing interleukin-10","volume":"7","author":"O\u2019Garra","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2024.112538_b0185","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.vaccine.2014.02.027","article-title":"Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release","volume":"32","author":"Ilyinskii","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2024.112538_b0190","doi-asserted-by":"crossref","first-page":"e0003546","DOI":"10.1371\/journal.pntd.0003546","article-title":"Coinjection with TLR2 agonist Pam3CSK4 reduces the pathology of leishmanization in mice","volume":"9","author":"Huang","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.intimp.2024.112538_b0195","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/IAI.00316-07","article-title":"Fc\u03b3RIII Mediates Immunoglobulin G-Induced Interleukin-10 and Is required for chronic leishmania mexicana lesions","volume":"76","author":"Thomas","year":"2008","journal-title":"Infect. Immun."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924010592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924010592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T17:22:07Z","timestamp":1722360127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924010592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":39,"alternative-id":["S1567576924010592"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112538","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PLGA nanoparticle-delivered Leishmania antigen and TLR agonists as a therapeutic vaccine against cutaneous leishmaniasis in BALB\/c mice","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112538"}}